Full Press Release Details
AMSTERDAM, the Netherlands, Oct. 7, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that it will be hosting an Investor Day and simultaneous webcast in New York City on October 15, 2015, starting at 8:30 a.m. uniQure management and invited guests will discuss the Company's strategy, clinical programs and uniQure's vision of how gene therapy will change the future of medicine.
Date: October 15, 2015
Time: 8:30 a.m. - approx. 12:00 p.m. ET
Venue: The Benjamin Hotel, 125 E. 50th Street, New York City, NY
J rn Aldag, Chief Executive Officer, uniQure
Deya Corzo, M.D., Senior Vice President, Research and Development, Liver/Metabolism, uniQure
Christian Meyer, M.D., Ph.D., Chief Medical Officer, uniQure
Patrick Most, M.D., Managing Director, uniQure GmbH
Harald Petry, Ph.D., Chief Scientific Officer, uniQure
Charles W. Richard, M.D., Ph.D., Senior Vice President, Research and Development, Neuroscience, uniQure
Chester B Whitley, Ph.D., M.D., Principal Investigator, Lysosomal Disease Network
Analysts and qualified investors who would like to register or learn more about the event should contact Blair Atkinson of MacDougall Biomedical Communications at +1 812 454 6257 or +1 781 235 3060 or batkinson@macbiocom.com. Registration is required as space is limited.
To access the webcast, log on http://edge.media-server.com/m/p/nroin5kw or go to the "Events" section on the "Media" page of uniQure's website, at http://www.uniqure.com/news/calendar-of-events. A replay of the webcast will be available on uniQure's website for at least 30 days following the event.
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com
Contact Data
Direct: +31 20 240 6100
Main: +31 20 566 7394
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +49 89 2424 3494
Contact
With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!
Already have an account? Log in here.